Search

Your search keyword '"Yana G Najjar"' showing total 79 results

Search Constraints

Start Over You searched for: Author "Yana G Najjar" Remove constraint Author: "Yana G Najjar"
Sorry, I don't understand your search. ×
79 results on '"Yana G Najjar"'

Search Results

1. 764 A phase 1, first-in-human (FIH), open-label, dose-finding and expansion study of XmAb808, a B7H3 x CD28 bispecific antibody, in combination with pembrolizumab in patients with advanced solid tumors

Catalog

Books, media, physical & digital resources

3. 43 Harnessing the power of glycoproteomics: a cutting-edge approach for predicting treatment efficacy in metastatic melanoma with immune checkpoint inhibitors

4. Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma

5. Search for effective treatments in patients with advanced refractory melanoma continues: can novel intratumoral therapies deliver?

6. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study

7. Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review

8. Supplementary Tables 1 and 6-8 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma

9. Supplementary Figure S1 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma

10. Supplementary Table 3 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma

11. Data from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma

12. Supplementary Table 2 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma

13. Supplementary Table 4 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma

15. Supplementary Figure S2 from Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma

16. Supplementary figure legend 1 from Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma

17. Supplementary figure legend 2 from Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma

18. Data from Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma

19. Obesity is associated with altered tumor metabolism in metastatic melanoma

21. Abstract CT109: First-in-class first-in-human phase 1 trial and translational study of the mono(ADP-ribose) polymerase-7 (PARP7) inhibitor RBN-2397 in patients with selected advanced solid tumors

22. Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma

23. Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients

24. 523 Preliminary clinical experience with XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors

25. Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis

26. An updated analysis of 4 randomized ECOG trials of high‐dose interferon in the adjuvant treatment of melanoma

27. Perspectives in immunotherapy: meeting report from the 'Immunotherapy Bridge' (December 4th-5th, 2019, Naples, Italy)

28. Phase II study of nivolumab (nivo) with relatlimab (rela) in patients (pts) with first-line advanced melanoma: Early on-treatment major pathologic response on biopsy

29. 435 A phase II trial of nivolumab plus axitinib in patients with anti-PD1 refractory advanced melanoma

30. 407 Preliminary safety, pharmacokinetics/pharmacodynamics, and antitumor activity of XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors

31. 75 Generalizability of potential biomarkers of response to CTLA-4 and PD-1 blockade therapy in cancer

32. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study

33. P854 Construction of the immune landscape of durable response to checkpoint blockade therapy by integrating publicly available datasets

34. Novel agents in renal carcinoma: a reality check

35. Abstract LB062: Efficacy of Responder-derived Fecal Microbiota Transplant (R-FMT) and Pembrolizumab in Anti-PD-1 Refractory Patients with Advanced Melanoma

36. Thick melanoma is associated with low melanoma knowledge and low perceived health competence, but not delays in care

37. Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma

38. Adjuvant Systemic Therapy for High-Risk Melanoma Patients

39. Impact of the COVID-19 pandemic on staging at presentation of patients with invasive melanoma

40. A phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with advanced melanoma

41. Characteristics of the Tumor Microenvironment That Influence Immune Cell Functions: Hypoxia, Oxidative Stress, Metabolic Alterations

42. Metastatic melanoma with sebocyte-like melanocytes and widespread visceral involvement

43. Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review

44. A phase I study of neoadjuvant combination immunotherapy in locally/regionally advanced melanoma

45. Association of medication (Med) and antibiotic (Abx) use with response and survival in advanced melanoma (MEL) receiving PD-1 inhibitors

46. Association of baseline neutrophil-to-lymphocyte ratio (NLR) with response and survival in advanced melanoma (MEL) receiving PD-1 inhibitors

47. Association of baseline body mass index (BMI) with response and survival in patients (Pts) with advanced melanoma (MEL) receiving PD-1 inhibitors

48. Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab

49. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

50. Myeloid derived suppressor cell subset accumulation in renal cell carcinoma parenchyma is associated with intratumoral expression of IL-1β, IL-8, CXCL5 and Mip-1α